Question 1

What is the difference between Verzenio and Ibrance?

Accepted Answer

Verzenio is Abemaciclib inhibits CDK4 and CDK6, blocking Rb phosphorylation and G1/S cell cycle progression. and is developed by Eli Lilly. Ibrance is Palbociclib inhibits CDK4/6 to block G1/S cell cycle progression in ER-positive breast cancer. and is developed by Pfizer.

Question 2

What are Verzenio and Ibrance used for?

Accepted Answer

Verzenio: Hormone receptor positive malignant neoplasm of breast, Human epidermal growth factor 2 negative carcinoma of breast. Ibrance: Hormone receptor positive malignant neoplasm of breast, Human epidermal growth factor 2 negative carcinoma of breast.

Question 3

Are Verzenio and Ibrance in the same drug class?

Accepted Answer

No — Verzenio is Kinase inhibitor and Ibrance is CDK4/6 inhibitor.

	Verzenio	Ibrance
Generic name	abemaciclib	Palbociclib
Sponsor	Eli Lilly	Pfizer
Drug class	Kinase inhibitor	CDK4/6 inhibitor
Molecular target	Cyclin-dependent kinases 4 and 6 (CDK4/CDK6)	Cyclin-dependent kinases 4 and 6 (CDK4/6)
Modality	—	Small molecule
Phase	FDA-approved	FDA-approved
Therapeutic area	Oncology	Oncology
First approval	2017	2015

Verzenio vs Ibrance

At a glance

Mechanism of action

Approved indications

Verzenio

Ibrance

Common side effects

Verzenio

Ibrance

Further reading

Verzenio	Abemaciclib inhibits CDK4 and CDK6, blocking Rb phosphorylation and G1/S cell cycle progression.
Ibrance	Palbociclib inhibits CDK4/6 to block G1/S cell cycle progression in ER-positive breast cancer.